Mostrar el registro sencillo del ítem

dc.rights.licenselicencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
dc.contributor.authorBuitrago Jimenez, Lina Maria
dc.contributor.authorLopera Jinete, Andrea Yuranis
dc.contributor.authorRivero Torres, Mayra Alejandra
dc.contributor.authorPeña Merlano, Engelbert
dc.date.accessioned2018-10-30T20:24:29Z
dc.date.available2018-10-30T20:24:29Z
dc.date.issued2016
dc.identifier.urihttp://hdl.handle.net/20.500.12442/2327
dc.description.abstractIntroducción La Diabetes Mellitus (DM) es considerada un problema de salud pública a nivel mundial no solo por las complicaciones propias de la patología, sino también por el costo económico que esto genera al sistema de salud. Esta se caracteriza por una deficiencia del páncreas para generar insulina que es una hormona encargada de introducir la glucosa a la célula. Más de un 90% de los individuos diabéticos sufren una DM tipo II, que es un trastorno progresivo con un indicio lento y sutil. Dentro de las complicaciones más frecuentes de esta patología se encuentran las enfermedades cardiovascular, estimada cada año en más de 1 millón de personas afectadas en Estados Unidos y más de 19 millones en el resto del mundo, desencadenando síndrome coronario agudo o la muerte súbita cardiaca. Objetivo: Asociar los factores de riesgo de enfermedad cardiovascular (ECV), en pacientes con diabetes mellitus (DM) tipo II a partir de revisión de historias clínicas para el establecimiento de criterio de manejo clínico; Caracterizar a los pacientes con DM tipo II según el Índice de masa corporal (IMC); Categorizar el grado de obesidad en los pacientes con DM tipo II; Comparar los pacientes diabéticos tipo II que presentan alto de riesgo en el perfil lipídico con los que no presentan. Materiales y métodos: Se realizó un estudio de cohorte retrospectivo a partir de la revisión de historias clínicas en el entro Endocrinológico del Caribe de la ciudad de Barranquilla, Colombia, correspondientes al periodo entre 2014 a 2016. La muestra estuvo representada por 107 mujeres con DM tipo 2 que cumpliesen los criterios de inclusión. Resultados: Obesidad: 49% con obesidad (17% grado 1, 22% grado 2 y 10% grado 3), 32% con sobrepeso, 18% con buen peso y el 1 % con delgadez; p= 0,024, OR= 1,73 e IC 95% 1,07-2,79. Perfil lipídico: 20% óptimo, 40% moderado y 40% alto. Este último con p= 0, 000, OR= 24,38 e IC 95% 12,55-47,37. Conclusiones: Tanto la obesidad como los lípidos elevados son factores de riesgo en los individuos de sexospa
dc.language.isospaspa
dc.publisherEdiciones Univerisidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.subjectDiabetesspa
dc.subjectEnfermedad Cardiovascularspa
dc.subjectInsulinorresistenciaspa
dc.subjectPerfil lipídicospa
dc.titleCaracterización del riesgo cardiovascular en la diabetes Tipo II período 2014 - 2016-1 en Barranquillaspa
dc.typeOtherspa
dcterms.referencesSeshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch. Pathol. Lab. Med., 2009;133 (2) :233-48.eng
dcterms.referencesBihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: look before you leap.Nephrol Dial Transplant. 2006; 21:1749-1752.eng
dcterms.referencesBolton WK, Vaughan ED. A comparative study of open surgical and percutaneous renal biopsies.J Urol 1977; 117:696-8.eng
dcterms.referencesRadford MG, Donadio JV, et al. Renal biopsy in clinical practice. Mayo ClinProc 1994; 69:983-4.eng
dcterms.referencesWieckre CG, Golper TA. Complications of percutaneous needle biopsy of the kidney. Am J Nephrol 1982; 2:173-8.eng
dcterms.referencesBrissler JJ. Hemothorax as a complication of percutaneous renal biopsy. Am J KidneyDis 1991; 18:122.eng
dcterms.referencesAgadjanyan, A.Peterson,J.Noteboom,K.C.O’Briant,A.Allen,D.W.Lin,N. Urban, C.W.Drescher,B.S.Knudsen,D.L.Stirewalt,R.Gentleman,R.L.Vessella, P.S. Nelson,D.B.Martin,M.Tewari,CirculatingmicroRNAsasstableblood- based markersforcancerdetection,Proc.Natl.Acad.Sci.U.S.A.105(2008) 10513–10518.eng
dcterms.referencesH.Zhao,J.Shen,L.Medico,D.Wang,C.B.Ambrosone,S.Liu,A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer,PLoS One 5(2010)e13735.eng
dcterms.referencesC.Roth,B.Rack,V.Muller,W.Janni,K.Pantel,H.Schwarzenbach,Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer,BreastCancerRes.12(2010)R90.eng
dcterms.referencesH.M.Heneghan,N.Miller,A.J.Lowery,K.J.Sweeney,J.Newell,M.J.Kerin,Circulating microRNAs as novel minimally invasive biomarkers for breastcancer, Ann. Surg.251(2010)499–505.eng
dcterms.referencesD.D.Taylor,C.Gercel-Taylor,MicroRNA signatures of tumor -derive dexosomes as diagnostic biomarkers of ovarian cancer,Gynecol.Oncol.110(2008)13–21.eng
dcterms.referencesTe JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, et al. 2010 Identification of Unique MicroRNA Signature Associated with Lupus Nephritis. PLoS ONE 5(5): e10344.eng
dcterms.referencesRuiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357:1027-32.eng
dcterms.referencesAustin HA. Clinical evaluation and monitoring of lupus kidney disease.Lupus 1998;7(9):618-621.eng
dcterms.referencesDomoto DT. The significance of electron dense deposits in mild lupus nephritis.Yale J BiolMed 1980;53:317-324.eng
dcterms.referencesCameron. Lupus nephritis. J Am SocNephrol 1999; 10(2):413-424eng
dcterms.referencesHricik, Chung-Park. Glomerulonephritis. New Engl J Med 1998;339(13):888-898.eng
dcterms.referencesGolbus J, McCune WJ. Lupus nephritis. Clasification, prognosis, immunopathogenesis and treatment.RheumClin North Am 1994;20:213-224.eng
dcterms.referencesBoumpas DT, Balow JE. Outcome criteria for lupus nephritis trials. A criticaloverview. Lupus 1998; 7(9):622-629.eng
dcterms.referencesAppel GB, Silva FG, Pirani CL, Melzer JI, Estes D. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification.Medicine. 1978;57:371–408.eng
dcterms.referencesWhittier WL, Korbet SM. Renal biopsy: update.CurrOpinNephrolHypertens 2004;13(6):661—5.eng
dcterms.referencesMattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? CurrOpinNephrolHypertens 1999;8(6):715—8.eng
dcterms.referencesHergesell O, Felten H, Andrassy K, Kühn K, Ritz E. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases.Nephrol Dial Transplant 1998;13(4):975—7.eng
dcterms.referencesSchwarz A, Gwinner W, Hiss M, Radermacher J, MengelM,Haller H. Safety and adequacy of renal transplant protocol biopsies.Am J Transplant 2005;5(8):1992—6.eng
dcterms.referencesManno C, Strippoli GF, Arnesano L, Bonifati C, Campobasso N, Gesualdo L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. KidneyInt 2004;66(4):1570—7.eng
dcterms.referencesEiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. ClinExpNephrol 2005;9(1):40—5.eng
dcterms.referencesStiles KP, Hill C, LeBrun CJ, Reinmuth B, Yuan CM, Abbott KC. The impact of bleeding times on major complication rates after percutaneous real-time ultrasoundguided renal biopsies.J Nephrol 2001;14(4):275—9.eng
dcterms.referencesFurness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates.Transplantation 2003;76(6):969—73.eng
dcterms.referencesSohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: Pathophysiology and clinical risk factors.Thromb Res 2006;118(3):417—22.eng
dcterms.referencesJohn P. Cogswell, et al. Identification of miRNAChanges in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways. Journal of Alzheimer'sDisease. 2008; 14(1): 27-41eng
dcterms.referencesJessica A. Weber, et al. The MicroRNA Spectrum in 12 Body Fluids.ClinicalChemistry 56: 1733-1741, 2010.eng
dcterms.referencesKohda Y, Murakami H, Moe OW, Star RA. Analysis of segmental renal gene expression by laser capturemicrodissection. KidneyInt. 57(1), 321–331 (2000).eng
dcterms.referencesWhite NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nat. Rev. Clin. Oncol. 8(2), 75–84 (2010).eng
dcterms.referencesAkkina S, Becker BN. MicroRNAs in kidney function and disease. Transl. Res. 157(4), 236–240 (2011).eng
dcterms.referencesLi JY, Yong TY, Michael MZ, Gleadle JM. Review: the role of microRNAs in kidney disease. Nephrology (Carlton)15(6), 599–608 (2010).eng
dcterms.referencesCastillo PL, Navarro JE, Arango QY, López AA, Mejía VV, González HJ et al. Asociación de obesidad con la enfermedad renal crónica de pacientes atendidos en la Clínica de la Costa. 2005-2014. Rev Colomb Nefrol. 2016; 3 (1):14-19.eng
dcterms.referencesLiang M, Liu Y, Mladinov D et al.MicroRNA: a new frontier in kidney and blood pressure research. Am. J. Physiol. Renal Physiol. 297(3), F553–F558 (2009).eng
dcterms.referencesTian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18(3), 404–411 (2008).eng
dcterms.referencesSun Y, Koo S, White N et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. NucleicAcids Res. 32(22), e188 (2004).eng
dcterms.referencesZhou H, Cheruvanky A, Hu X et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. KidneyInt. 74(5), 613–621 (2008).eng
dcterms.referencesBorchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. AutoimmunRev 9:A277–A287eng
dcterms.referencesLawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. ArthritisRheum 41:778–799eng
dcterms.referencesLang B, Silverman E. A clinical overview of systemic lupus erithematosus in childhood. Pediatrics Review.1993;14:194-20eng
dcterms.referencesCervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Med (Baltimore) 82:299–308eng
dcterms.referencesSanchez-Vegazo I, et al. Nefritis lúpica. REV ESP PATOL 2002; Vol 35, n.º 3: 269-27spa
dcterms.referencesAnaya JM, Uribe M, Pinto LF, Matute G, Molina JF, Calle I. Nefritis Lúpica. Definición clínica, patológica y terapéutica. RevColombReumatol 2001; 8: 61-74spa
dcterms.referencesTan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. ArthritisRheum 1982; 25:1271-1277eng
dcterms.referencesWeening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. Theclassification of glomerulonephritis in systemic lupus erithematousrevisited. J Am SocNephrol 15:241-250, 2004.eng
dcterms.referencesChurg J, Bernstein J, Glassock RJ. Lupus nephritis. En: Classification and Atlas of Glomerular Disease, 2nd ed. New York, Igaku-Shoin, 1995, p51.eng
dcterms.referencesMitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. ProcNatlAcadSci U S A 2008;105:10513eng
dcterms.referencesGilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoSOne 2008;3:e3148.eng
dcterms.referencesHanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNAas tumor marker: microRNA-126 and microRNA182 are related to urinary bladder cancer. UrolOncol 2010;28:655–61eng
dcterms.referencesBoeri M. et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. NatlAcad. Sci. USA 108, 3713–3718 (2011).eng
dcterms.referencesRICE P, LONGDEN I, BLEASBY A. EMBOSS: the European Molecular Biology Open Software Suite. TrendsGenet. 2000; 16(6):276-7eng
dcterms.referencesALTSCHUL S F, GISH W, MILLER W, MYERS E W, LIPMAN D J. Basic local alignment search tool. J. Mol. Biol. 1990; 215:403-410.eng
dcterms.referencesGRIFFITHS-JONES S, SAINI HK, VAN DONGEN S, ENRIGHT AJ. miRBase: tools for microRNA genomics. NucleicAcids Res. 2008; 36 D154-D158 (www.mirbase.org).eng
dcterms.referencesLI W, GODZIK A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006; 22:1658-9eng
dcterms.referencesK. Zen, C.Y. Zhang, Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers, Med. Res. Rev (2010).eng
dcterms.referencesJ.L. Weickmann, D.G. Glitz, Human ribonucleases. Quantitation of pancreaticlike enzymes in serum, urine, and organ preparations, J. Biol. Chem. 257 (1982) 8705– 8710.eng
dcterms.referencesD.J. Gibbings, C. Ciaudo, M. Erhardt, O. Voinnet, Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity, Nat. Cell Biol. 11 (2009) 1143–1149.eng
dcterms.referencesH. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, J.O. Lotvall, Exosome mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol. 9 (2007) 654–659.eng
dcterms.referencesH. Iguchi, N. Kosaka, T. Ochiya, Secretory microRNAs as a versatile communication tool, Commun. Integr. Biol. 3 (2010) 478–481.eng
dcterms.referencesG. Camussi, M.C. Deregibus, S. Bruno, V. Cantaluppi, L. Biancone, Exosomes/microvesicles as a mechanism of cell-to-cell communication, Kidney Int. 78 (2010) 838–848.eng
dcterms.referencesV. Muralidharan-Chari, J.W. Clancy, A. Sedgwick, C. D’Souza-Schorey, Microvesicles: mediators of extracellular communication during cancer progression, J. Cell Sci. 123 (2010) 1603–1611.eng
dcterms.referencesK. Wang, S. Zhang, J. Weber, D. Baxter, D.J. Galas, Export of microRNAs and microRNA-protective protein by mammalian cells, Nucleic Acids Res. 38 (2010) 7248–7259.eng
dcterms.referencesN. Kosaka, H. Iguchi, Y. Yoshioka, F. Takeshita, Y. Matsuki, T. Ochiya, Secretory mechanisms and intercellular transfer of microRNAs in living cells, J. Biol. Chem. 285 (2010) 17442–17452.eng
dcterms.referencesH. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, J.O. Lotvall, Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol. 9 (2007) 654–659.eng
dcterms.referencesM.P. Hunter, N. Ismail, X. Zhang, B.D. Aguda, E.J. Lee, L. Yu, T. Xiao, J. Schafer, M.L. Lee, T.D. Schmittgen, S.P. Nana-Sinkam, D. Jarjoura, C.B. Marsh, Detection of microRNAexpression in human peripheralbloodmicrovesicles, PLoSOne 3 (2008) e3694.eng
dcterms.referencesA. Michael, S.D. Bajracharya, P.S. Yuen, H. Zhou, R.A. Star, G.G. Illei, I. Alevizos, Exosomes from human saliva as a source of microRNA biomarkers, Oral Dis. 16 (2010) 34–38.eng
dcterms.referencesI. Dimov, L. JankovicVelickovic, V. Stefanovic, Urinary exosomes, ScientificWorldJournal 9 (2009) 1107–1118.eng
dcterms.referencesD.M. Pegtel, K. Cosmopoulos, D.A. Thorley-Lawson, M.A. van Eijndhoven, E.S. Hopmans, J.L. Lindenberg, T.D. de Gruijl, T. Wurdinger, J.M. Middeldorp, Functional delivery of viral miRNAs via exosomes, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 6328–6333.eng
dcterms.referencesMendinueta Martínez M, Herazo Beltrán Y. Factores de Riesgo Cardiovasculares en Trabajadores de una Empresa Productora de Grasas y Aceites Vegetales. Cienc. innov. salud. 2015; 3(1):23–26. DOI 10.17081/innosa.3.1.235spa
dcterms.referencesValdés DO, Chávez PE, Torres BF. Comportamiento de las crisis hipertensivas en un grupo de pacientes hipertensos. Cienc. innov. salud. 2014; 2 (1):44-45. DOI 10.17081/innosa.2.1.72spa
dcterms.referencesVelez C, Vidarte JA. Discapacidad y Determinantes Sociales de la Salud Estructurales e Intermedios: Diferencias por Género. Cienc. innov. salud. 2014; 2 (2):63 – 69. DOI 10.17081/innosa.2.2.42spa
dcterms.referencesGarcía Puello F. Autopercepción de Salud y Envejecimiento. Cienc. innov. salud. 2013; 1(1):69-77. DOI 10.17081/innosa.1.1.87spa
sb.sedeSede Barranquillaspa
sb.programaMedicinaspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccess


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem